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Inappropriate activation of mammalian/mechanistic target of rapamycin complex 1
(mTORC1) is common in cancer and has many cellular consequences including elevated
endoplasmic reticulum (ER) stress. Cells employ autophagy as a critical compensatory sur-
vival mechanism during ER stress. This study utilised drug-induced ER stress through nel-
finavir in order to examine ER stress tolerance in cell lines with hyper-active mTORC1
signalling. Our initial findings in wild type cells showed nelfinavir inhibited mTORC1 sig-
nalling and upregulated autophagy, as determined by decreased rpS6 and S6K1 phosphor-
ylation, and SQTSM1 protein expression, respectively. Contrastingly, cells with hyper-
active mTORC1 displayed basally elevated levels of ER stress which was greatly exagger-
ated following nelfinavir treatment, seen through increased CHOP mRNA and XBP1
splicing. To further enhance the effects of nelfinavir, we introduced chloroquine as an
autophagy inhibitor. Combination of nelfinavir and chloroquine significantly increased
ER stress and caused selective cell death in multiple cell line models with hyper-active
mTORC1, whilst control cells with normalised mTORC1 signalling tolerated treatment.
By comparing chloroquine to other autophagy inhibitors, we uncovered that selective
toxicity invoked by chloroquine was independent of autophagy inhibition yet entrapment
of chloroquine to acidified lysosomal/endosomal compartments was necessary forC, acetyl-CoA carboxylase; AMPK, AMP-dependent protein kinase; ANOVA, analysis of vari-
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 6 7 5e6 8 8676cytotoxicity. Our research demonstrates that combination of nelfinavir and chloroquine
has therapeutic potential for treatment of mTORC1-driven tumours.
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reserved.1. Introduction compromised stress recovery pathways in cancer cells mayThe mammalian/mechanistic target of rapamycin complex 1
(mTORC1) pathway is frequently hyper-activated in cancer.
mTORC1 regulates many processes linked to cancer, such as
cell growth, proliferation, metastasis, autophagy, metabolism
and angiogenesis. mTORC1 hyper-activation through genetic
mutations of upstream components also underlies several
tumour predisposition syndromes, such as tuberous sclerosis
complex (TSC) and Cowden disease/PTEN hamartoma syn-
drome (Krymskaya and Goncharova, 2009). TSC is an auto-
somal dominant condition caused through mutations in
either TSC1 or TSC2 and is characterised by tumour growth in
multiple organs, neurocognitive problems and epilepsy (for re-
view see Kohrman, 2012). The TSC1 and TSC2 tumour suppres-
sor proteins together with TBC1D7 form a functional complex
which has GTPase-activating protein activity towards Ras ho-
mologue enriched in brain (Rheb). Rheb-GTP potently activates
mTORC1, while conversion of Rheb-GTP to an inactive GDP-
bound state by TSC1/TSC2/TBC1D7 turns off mTORC1 (Tee
et al., 2003; Dibble et al., 2012). Consequently, loss-of-function
mutations in either TSC1 or TSC2 cause aberrant signal trans-
duction through mTORC1. Mutations of TSC1, TSC2 and mTOR
occur in some sporadic cancers, but more common compo-
nents within mitogenic signalling upstream of mTORC1 are
altered, such as PTEN or RAS within PI3K and MAPK pathways,
respectively. TSC1 is mutated in approximately 15% of bladder
cancers and 3% of clear cell renal carcinomas; TSC2 is mutated
in 3% of bladder cancers and in 8% of well-differentiated
pancreatic neuroendocrine tumours and activating mTOR ki-
nase domain mutations have been identified in intestinal ade-
nocarcinomas and clear cell renal carcinomas (Platt et al., 2009;
Sjodahl et al., 2011; Jiao et al., 2011). Frequent mutations
affecting the wider PI3K/PTEN-Akt-mTOR signalling network
have also been reported in clear cell renal cancers and head
and neck cancer (Sato et al., 2013; Liao et al., 2011).
Aberrant signalling through mTORC1 is known to enhance
the basal levels of ER stress, which is done in part by height-
ened levels of de novo protein synthesis, leading to an accumu-
lation of unfolded proteins within the ER (Kang et al., 2011;
Ozcan et al., 2008). mTORC1 further enhances the burden of
ER stress through autophagy repression, as autophagy is uti-
lised by the cell to remove unfolded protein aggregates to
restore the protein folding environment within the ER
(Høyer-Hansen and J€a€attel€a, 2007). Related work highlighting
the crosstalk between autophagy and ER homeostasis showed
that induction of ER stress by thapsigargin was via impair-
ment of autophagosomeelysosome fusion (Ganley et al.,
2011). Elevated cell stress is common in cancer and could
potentially be exploited therapeutically (Hanahan and
Weinberg, 2011). For instance, it is recognised thatconfer sensitivity to stress-inducing drugs as many cancer
cell lines are sensitive to endoplasmic reticulum (ER) stress-
inducers (Liu et al., 2012; Li et al., 2013; Zang et al., 2009), where
excessive or prolonged ER stress leads to cell death (for review
see Appenzeller-Herzog and Hall, 2012).
The mTOR inhibitor and rapamycin analogue, everolimus,
is licensed for the treatment of renal angiomyolipomas and
subependymal giant cell astrocytomas in patients with TSC
(Kohrman, 2012). However, rapalogues only induce partial
regression of tumour volume and the tumours often regrow
following treatment cessation (Franz and Weiss, 2012).
Evidently, alternative therapeutic strategies must be explored
for mTORC1-driven tumours and targeting existing stress
pathways is one possibility. Ozcan et al. (2008) and Di Nardo
et al. (2009) demonstrated that Tsc2/ cells elicited a higher
level of ER stress that was dependent on aberrant signalling
through mTORC1. In addition, tumours derived from TSC pa-
tients were also observed to have increased levels of ER stress.
Supporting the notion that targeting this already elevated ER
stress pathway in Tsc2/ cells is a therapeutic option, both
cellular and murine models of TSC have proved to be sensitive
to ER stress-inducers such as thapsigargin (Siroky et al., 2012;
Kang et al., 2011; Ozcan et al., 2008). ER stress upregulates auto-
phagy as part of the unfolded protein response; a cytoprotec-
tive process purposed to alleviate ER stress through removal
of misfolded protein products (He and Klionsky, 2009). Cells
lacking Tsc2 show an attenuated autophagic response due to
mTORC1-mediated repression despite elevated levels of ER
stress (Siroky et al., 2012; Parkhitko et al., 2011).
In this study we utilised nelfinavir, an ER stress-inducer
that was originally clinically approved for treatment of human
immunodeficiency virus infection. Nelfinavir was more
recently observed to have anti-cancer activity in pre-clinical
cell and xenograft models and is currently being investigated
in multiple clinical trials (Buijsen et al., 2013; Pan et al., 2012;
Rengan et al., 2012; Alonso-Basanta et al., 2014). Nelfinavir
has been shown to affect many cellular processes linked to
ER homeostasis including proteasome inhibition, impairment
of signal transduction through the PI3K/Akt pathway and in-
duction of autophagy, although some actions appear cell
type dependent (Gills et al., 2007). We also employed chloro-
quine, a widely-used anti-malarial drug which has multiple
effects on cells including alteration ofmitochondrial and lyso-
somalmembrane potential and arrest of autophagy flux in the
later stages through alteration of lysosomal pH (Poole and
Ohkuma, 1981). There is current interest in the clinical use
of chloroquine in combination with conventional and novel
anti-cancer agents (Goldberg et al., 2012; Solomon and Lee,
2009; Sotelo et al., 2006). The rational for the use of chloro-
quine in these combinations is often inhibition of a presumed
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evidence in some contexts that the cytotoxic action of chloro-
quine may be largely independent of autophagy inhibition
(Maycotte et al., 2012; Harhaji-Trajkovic et al., 2012; Seitz
et al., 2013). Herein, we examined the effects of nelfinavir
and chloroquine in multiple cell line models with hyper-
activated mTORC1 signalling and elevated basal levels of ER
stress. Unlike previous studies in cancer cell lines, we were
able to test the hypothesis that loss of Tsc2 and consequent
mTORC1 activation specifically sensitises cells to drug-
induced ER stress and cell death. Importantly, we directly
compared the effectiveness of nelfinavir and chloroquine in
Tsc2/ cell lines with matched controls expressing wild-
type Tsc2 before validating our findings in a human non-
small cell lung cancer cell line known to have aberrant
mTORC1 signalling due to an oncogenic KRAS mutation. We
found chloroquine promotes nelfinavir-induced ER stress
and cell death in mTORC1-hyperactive cells in an
autophagy-independent manner. Our data suggests a novel
therapeutic approach for killing tumour cells which have
aberrant levels of mTORC1 activity and higher basal levels of
ER stress.2. Materials and methods
2.1. Cell culture and reagents
Tsc2þ/þ p53/ and Tsc2/ p53/mouse embryonic fibro-
blasts (MEFs) were kindly provided by David J. Kwiatkowski
(Harvard University, Boston, USA). Tsc2/ ETL3 (Eker rat
leiomyoma-derived cells) and control ELT3-Tsc2 cells in which
Tsc2 is re-expressed were kindly provided by Cheryl Walker
(M.D. AndersonCancer Center, Houston, USA). Human embry-
onic kidney 293 (HEK293) cells and human lung carcinoma
(NCI-H460) cells were purchased from ATCC. All cell lines
were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM), supplemented with 10% (v/v) foetal bovine serum
(FBS), 100 U/ml penicillin and 100 m/ml streptomycin (Life
Technologies Ltd., Paisley, UK) in a humidified incubator at
37 C, 5% (v/v) CO2. Nelfinavir mesylate hydrate, chloroquine
di-phosphate salt, mefloquine hydrochloride, bafilomycin-
A1, 3-methyladenine (3-MA) and thapsigargin were purchased
from SigmaeAldrich Company Ltd. (Dorset, UK). Nelfinavir,
mefloquine, bafilomycin-A1 and thapsigargin were dissolved
in dimethyl sulfoxide (DMSO) at 30 mM, 50 mM, 2.5 mM and
10 mM stock solutions, respectively. Chloroquine was dis-
solved in fresh culture medium to a 100 mM stock and further
diluted in culture medium to the required concentrations for
use. 3-MA was dissolved in dH2O to a concentration of
100 mM. Drug(s) or DMSO vehicle control was added to cell
culture medium in a manner that kept the final DMSO vehicle
concentration below 0.5% (v/v).
2.2. mRNA extraction and reverse transcription
Cells were plated onto 6 cm2 plates and allowed to adhere
overnight. Following the appropriate treatment, cells were
first washed in phosphate buffered saline (PBS) then lysed us-
ing 1 ml RNAprotect Cell Reagent (Qiagen, West Sussex,United Kingdom). RNA was extracted using the RNeasy Plus
mini kit (Qiagen). Cell lysates were homogenized using Qiash-
redders (Qiagen) during the RNA extraction procedure. The
concentration and purity of RNA was determined by
measuring the absorbance at 260 nm and 280 nm in a Nano-
drop spectrophotometer (Thermo Scientific, Hemel
Hempsted, UK). Total RNA from each sample (1 mg) was tran-
scribed into cDNA using Quantitect reverse transcription kit
(Qiagen) in a thermal cycler (Applied Biosystems, California,
USA). RNA, gDNA wipeout buffer and RNase-free water at a
final volume of 14 ml were incubated at 42 C for 2min. Quanti-
script Reverse Transcriptase (Qiagen), Quantiscript RT buffer
(Qiagen) and primers were added to a final volume of 20 ml
and samples incubated at 42 C for 15 min followed by 95 C
for 3 min.
2.3. Detection of endoplasmic reticulum stress
Quantitative PCR (Q-PCR) reactions were conducted in 96 well
plates (Thermo Fisher, Loughborough, UK) using 25 ng DNA
per reaction, appropriate primer sets and SYBR Green PCR
Master mix (Qiagen). Quantitect b-actin and C/EBP Homolo-
gous Protein (CHOP) primers were purchased from Qiagen.
Q-PCR was performed using an Applied Biosystems 7500
real-time cycler as follows: initial denaturation step (95 C,
15 min); 40 cycles of denaturation (94 C, 15 s); annealing
step (55 C, 30 s); extension step (72 C, 30 s). The amplification
productswere quantified during the extension step in the 40th
cycle. Relative quantification was performed using the
comparative CT method (ddCT) with b-actin as reference
gene and DMSO vehicle-treated Tsc2þ/þ MEFs as the cali-
brator. Melting curve analysis was performed to verify their
specificity of the RT-PCR products. XBP1 primers [Forward:
50-AAA CAG AGT AGC AGC TCA GAC TGC-30, Reverse: 50-TCC
TTC TGG GTA GAC CTC TGG GA-3
0
] were synthesised through
MWG Operon-Eurofin (Ebersberg, Germany). PCR was per-
formed using an Applied Biosystems GeneAmp 9700 PCR sys-
tem as follows: initial denaturation step (98 C, 3 min); 31
cycles of denaturation (9 C, 30 s); annealing step (60 C,
30 s); extension step (72 C, 1 min). XBP1 products were run
on 3% (w/v) agarose gels, 1 TriseAcetateeEDTA (pH 8.0) us-
ing GelRed nucleic acid stain (Cambridge Bioscience, Cam-
bridge, UK). DNA samples were prepared for loading by the
addition of 5 loading buffer. PCR products of X-box binding
protein 1 (XBP1) were 480 bp, unspliced, and 454 bp, spliced.
2.4. Antibodies and western blotting
Antibodies towards ribosomal protein S6 (rpS6), phospho-rpS6
(Ser235/236), p70-S6 kinase 1 (S6K1), phospho-S6K1 (Th389),
Acetyl-CoA carboxylase (ACC), phospho-ACC (Ser79), AMP-
dependent protein kinase (AMPK), phospho-AMPK (Thr172),
binding immunoglobulin protein (BiP), inositol-requiring and
ER-to-nucleus signalling protein 1a (IRE1a), TSC2 and b-actin
were purchased from Cell Signaling Technology (Danvers,
USA). LC3 antibody was purchased from Novus Ltd. (Cam-
bridge, UK), while the antibody for Sequestesome 1 (SQSTM1)
was purchased from Progen Biotecknik (Heidelberg, Germany).
Cells were washed in PBS and then lysed in radio immunopre-
cipitation assay (RIPA) buffer (SigmaeAldrich) supplemented
Figure 1 e Nelfinavir-induced ER stress is more pronounced in
Tsc2L/L MEFs. Tsc2L/L and Tsc2D/D MEFs were treated with
either DMSO vehicle alone, 20 mM nelfinavir (NFV), or 1 mM
thapsigargin (TPG) for 3 h. Cells were then appropriately harvested
to analyse A) CHOP mRNA, which was standardised against b-actin
mRNA (n[ 3, *p< 0.05), B) PCR products for XBP1 mRNA were
resolved on agarose gels (unspliced [ 480 bp upper band,
spliced [ 454 bp lower band). b-actin is shown as a control. C)
Protein extracts were analysed for BiP, IRE1a and b-actin levels.
n [ 3, *p [<0.05.
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phosphatase inhibitor cocktail (Roche Diagnostics Ltd., Burgess
Hill, UK) and 1mMdithiothreitol (DTT) at 4 C. Following centri-
fugation at 13,000 rpm for 8min at 4 C, protein concentrations
were optimised by Bradford assay (SigmaeAldrich). Samples
were diluted in 4 NuPAGE loading sample buffer (Life Tech-
nologies) with 25mMDTT and boiled at 70 C for 10min.West-
ern blot was performed as previously described (Dunlop et al.,
2011). b-actinwas used to as a control for equal protein loading.
2.5. Cell viability assay
Cells were plated at 100% confluency (5 103/well) in a 96-well
plate. Drug or DMSO vehicle was added and the plates incu-
bated at 37 C for 48 h. Media was removed from the cells
and the plates frozen at 80 C. Following thawing, 200 ml
CyQuantmix, prepared as described in the CyQUANT Cell Pro-
liferation Assay (Life Technologies)manufacturer’s handbook,
was added to each well. Fluorescence was measured using a
FLUOstar OPTIMA fluorometer (BMG LABTECH, Buckingham-
shire, UK) at 485 nm and 520 nm. To determine cell number,
counted cells were co-analysed as a standard curve. Results
are expressed relative to untreated Tsc2þ/þ cells which are
assigned a value of 100%.
2.6. DNA fragmentation ELISA
DNA fragmentation was measured with the Cell Death Detec-
tion ELISA kit (Roche) according to the manufacturer’s proto-
col. This one-step colorimetric sandwich ELISA allows
relative quantification of histone-complexed DNA fragments
which are indicative of apoptosis. 5  103 cells were plated
in 96-well plates and incubated overnight. Drugs were added
to the required concentration and cells were incubated for
48 h. The relative quantity of immobilized antibodyehistone
complex was determined photometrically with absorbance
at 405 nm using 2,2
0
-azino-bis-3-ethylbenzothiazoline-6-
sulfonic acid as a peroxidase substrate. Results are expressed
relative to untreated Tsc2þ/þ cells which were assigned a
value of 1.
2.7. Late cell death assay
For assessment of cell viability, treated cells were incubated
with 3 mM DRAQ7 for 10 min at 37 C prior to flow cytometry
using excitation at 488 nm and detection of fluorescence in
log mode at wavelengths greater than 695 nm (far red). Flow
cytometry was performed using a FACS Calibur flow cytome-
ter (Becton Dickinson, Cowley, UK) and Cell Quest Pro soft-
ware (Beckton Dickinson Immunocytometry Systems) was
used for signal acquisition. To control for autofluorescence,
unstained cells were also analysed. Correlated signals were
collected for a minimum of 10,000 events.
2.8. Statistical analysis
Experiments were carried out at least 3 times. Where appli-
cable, results are expressed as mean  standard deviation
(SD). Student’s t-test and ANOVA were used and significance
reported at p  0.05.3. Results
3.1. Nelfinavir induces ER stress in Tsc2/ MEFs
We initially assessed ER stress after 3 h treatment with 20 mM
nelfinavir in Tsc2þ/þ and Tsc2/ MEF cell lines by measure-
ment of CHOP mRNA (Figure 1A). In DMSO vehicle treatment,
Tsc2/ MEFs had over 3-fold increase in relative expression
of CHOP mRNA compared to wild-type MEFs, which indicates
an elevated basal level of ER stress in the absence of Tsc2.
Although nelfinavir increased CHOP mRNA levels in both
cell lines, relative expression was more pronounced in the
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Figure 1A). These data suggest that the Tsc2/ MEFs are
more sensitive to nelfinavir-induced ER stress than the wild-
type cells, which is concurrent with previous findings (Ozcan
et al., 2008). Thapsigargin, a potent inducer of ER stress, served
as a positive control which enhanced CHOPmRNA expression
in both MEF cell lines. To confirm ER stress-induction, we also
analysed XBP1 mRNA splicing as a reliable readout of
nelfinavir-induced ER stress (Br€uning, 2011). We observed a
higher basal level of XBP1 mRNA splicing in Tsc2/ cells
(Figure 1B) and nelfinavir also selectively induced ER stress
in the Tsc2/ MEFs as observed by increased splicing
(compare lane 5 versus lane 2). In both MEF cell lines, thapsi-
gargin led to complete XBP1 mRNA splicing. We next
measured protein expression of BiP and IRE1a which are
considered common markers of ER stress (Figure 1C). Both
BiP and IRE1a protein levels were elevated in the Tsc2/
MEFs, which further confirms that cells lacking Tsc2 have a
higher basal level of ER stress. However, 3 h treatment of
either nelfinavir or thapsigargin failed to further enhance
BiP or IRE1a protein in the Tsc2/ MEFs, presumably as ER
stress levels were already basally high (Siroky et al., 2012;
Kang et al., 2011; Ozcan et al., 2008).
3.2. Nelfinavir inhibits mTORC1 signal transduction
and induces autophagy
Wenext analysedmTORC1 signal transduction in the Tsc2þ/þ
and Tsc2/ MEFs by examining rpS6 phosphorylation
(Figure 2A). In the Tsc2þ/þ MEFs, we observed complete inhi-
bition of rpS6 phosphorylation after nelfinavir treatment but
inhibition of mTORC1 signalling was incomplete in the
Tsc2/ MEFs, which reveals nelfinavir requires Tsc2 for full
repression of mTORC1 signalling. Cell quantification assays
revealed that nelfinavir reduced the number of Tsc2/ cells
by 16%, whereas Tsc2þ/þ MEFs were unaffected (Figure 2B).
Furthermore, there was a 3-fold increase in DNA fragmenta-
tion of Tsc2/MEFs compared to Tsc2þ/þ after 48 h exposure
to nelfinavir (Figure 2C), which indicates that loss of Tsc2 sen-
sitises cells to nelfinavir-induced cytotoxicity. Given that
autophagy is modulated by both mTORC1 and ER stress, we
next examined markers of autophagy after treatment with
nelfinavir. Untreated Tsc2/ MEFs had a lower level of auto-
phagy when compared to the Tsc2þ/þ MEFs, as observed by
increased protein accumulation of SQSTM1 (Figure 2D). Both
nelfinavir and thapsigargin increased autophagy as observed
by decreased SQSTM1 protein. Increased LC3 lipidation to
the lower resolving LC3-II isoform suggest either increased
autophagy or a block in late stage autophagy (or both).
Furthermore, we observed marked activation of AMPK upon
treatment with nelfinavir, via increased phosphorylation of
AMPK and its substrate, ACC (Figure 2D).
To validate some of our initial findings, we examined the
effects of nelfinavir on mTORC1 signalling and autophagy af-
ter acute insulin stimulation in HEK293 cells (Figure 2E). The
high level of insulin-induced rpS6 phosphorylation was
completely abolished upon treatment with nelfinavir.
SQSTM1 protein levels were also markedly reduced with nel-
finavir, which again suggests enhanced autophagy fluxing.
Similar to the effects we observed in the MEF cell lines, bothnelfinavir and thapsigargin strongly induced LC3-II
accumulation.
3.3. Chloroquine enhances nelfinavir-induced cell death
in Tsc2/ cells
Given that autophagy is a well-established survival mecha-
nism employed by cells to alleviate ER stress, we wanted to
determine whether inhibition of autophagy would enhance
the potency of nelfinavir to selectively kill Tsc2/ cells. To
do this we used chloroquine which blocks autophagy during
the final stages. Analysis of S6K1 phosphorylation revealed
that chloroquine alone did not affect mTORC1 signal trans-
duction but combination with nelfinavir was particularly
effective at reducing S6K1 phosphorylation in Tsc2þ/þ MEFs
and modestly in Tsc2/MEFs (Figure 3A). Chloroquine treat-
ment blocked autophagy, more effectively in the presence of
nelfinavir, as observed by an accumulation of LC3-II
(Figure 3A). In the Tsc2/ MEFs, a combination of nelfinavir
and chloroquine was much more effective at induction of
CHOP mRNA levels (by 27%, Figure 3B) and XBP1 splicing
(Figure 3C), than either agent alone.
We nextmeasured cell death by flow cytometry after stain-
ing with DRAQ7. DRAQ7 is a membrane impermeable far-red
fluorescence DNA-binding stain that is used to measure cell
death as a consequence of increasedmembrane permeability.
Events were gated to exclude fragmented cells and debris
before gating viable and non-viable populations according to
DRAQ7 staining. Combined 24 h treatment with nelfinavir
and chloroquine selectively killed Tsc2/MEFs by an average
of 43% compared to 6% cell death in Tsc2þ/þ MEFs (Figure 4A
and B). Using DNA fragmentation ELISA we found 48 h com-
bined nelfinavir and chloroquine led to over 5-fold increase
in relative DNA fragmentation in Tsc2/ MEFs when
compared to nelfinavir treatment alone (Figure 4C).
3.4. Enhancement of nelfinavir-induced cell death is not
due to autophagy inhibition by chloroquine
To confirm that enhancement of nelfinavir-induced cell death
was due to autophagy inhibition by chloroquine, Tsc2þ/þ and
Tsc2/ MEFs were treated with two other known inhibitors
of autophagy, bafilmycin-A1 and 3-methyladenine (3-MA), in
combination with nelfinavir. Analysis by western blot
following 3 h of treatment confirmed bafilomycin-A1 inhibited
autophagy comparable to chloroquine, as shown by increased
levels of SQSTM1 and LC3-II (Figure 5A). 3-MA is known to
have differing effects on autophagy depending on nutrient
status (Wu et al., 2010). Therefore, the lack of observed auto-
phagy inhibition by 3-MA was unsurprising. Interestingly,
24 h treatment with combined nelfinavir and bafilomycin-A1
or nelfinavir and 3-MA failed to induce Tsc2/ cell death to
a similar extent as combined nelfinavir and chloroquine (on
average 3% and 7% vs 25%, respectively, Figure 5BeC). To
determine whether cell death was exclusive to chloroquine,
we analysed the chloroquine analogue, mefloquine, and
found it to be highly effective at killing Tsc2/MEFs in com-
bination with nelfinavir (on average 63%). Further supporting
autophagy inhibition is not the underlying mechanism by
how these chloroquine compounds sensitise Tsc2/ cells to
Figure 2 e Nelfinavir inhibits mTORC1, induces autophagy and selectively kills Tsc2L/L MEFs. Tsc2L/L and Tsc2D/D MEFs were treated
with either DMSO vehicle alone, 20 mM nelfinavir (NFV), or 1 mM thapsigargin (TPG) for 3 h. A) Total and phosphorylated ‘(P)-rpS6’, TSC2 and
b-actin were determined by western blot analysis from total protein lysates. 48 h DMSO and 20 mM nelfinavir-treated Tsc2L/L and Tsc2D/D
MEFs were subjected to B) cell viability and C) cell death assays. D) Samples (prepared as for A) were subjected to western blot analysis to
determine total and phosphorylated ‘(P)-AMPK’, total and phosphorylated ‘(P)-ACC’, and LC3 (‘LC3-I’ and ‘LC3-II’). E) HEK293 cells were pre-
treated with either 20 mM nelfinavir or 1 mM thapsigargin as indicated for 30 min prior to 100 nM insulin stimulation for 30 min. Total and
phosphorylated ‘(P)-rpS6’, LC3 (‘LC3-I’ and ‘LC3-II’) and b-actin were then determined by western blot analysis from prepared cell lysates. n[ 3,
*p [<0.05.
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by low levels of SQSTM1 and no accumulation of lipidated
LC3-II, Figure 5A). Collectively, our data implies that chloro-
quine sensitises nelfinavir-induced cell death via a mecha-
nism that is not autophagy inhibition. To explore other
possible mechanisms of drug action, we combined nelfinavirand chloroquine treatmentwith bafilomycin-A1, which blocks
the v-ATPase and prevents entrapment of chloroquine to lyso-
somes and late endosomes. We observed that bafilomycin-A1
robustly rescued cell death by nelfinavir and chloroquine in
the Tsc2/ MEFs (Figure 5B). This indicates that entrapment
of chloroquine to acidified lysosomes and late endosomal
Figure 3 e Chloroquine further sensitises Tsc2L/L MEFs to
nelfinavir-induced ER stress. Tsc2L/L and Tsc2D/D MEFs were
treated with DMSO vehicle alone, 20 mM nelfinavir (NFV), and/or
chloroquine (CQ, 10 mM and 20 mM) as indicated. A) Following 3 h
drug treatment, protein lysates were subjected to western blot analysis
to determine levels of total and phosphorylated ‘(P)-rpS6’, total and
phosphorylated ‘(P)-S6K1’, LC3-II, TSC2 and b-actin. B) CHOP
mRNA was analysed and standardised against b-actin (n [ 3,
*p< 0.05). C) PCR products for XBP1 mRNA were resolved on
agarose gels (unspliced[ 480 bp upper band, spliced[ 454 bp lower
band). b-actin mRNA is shown as a control. n [ 3, *p [<0.05.
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enhancement of nelfinavir-induced cell death.
To confirm the cytotoxic effects of combined nelfinavir and
chloroquine, we utilised anotherwell-established Tsc2/ cell
line model, the ELT3 rat smooth muscle cell line (Eker et al.,
1983). Similar to the MEFs, 3 h combined treatment with nelfi-
navir and chloroquine reduced phosphorylation of S6K1, low-
ered SQSTM1 protein and enhanced levels of LC3-II in ELT3-V3
(Tsc2/) cells (Figure 6A). Cell viability was significantlyreduced in ELT3-V3 cells compared to ELT-T3 cells following
48 h of combined nelfinavir and chloroquine treatment
(Figure 6B). Cell death assays following 48 h of treatment
showed selective cell death in ELT3-V3 cells by an average of
34% compared to 9% in ELT3-T3 (Tsc2þ/þ) cells (Figure 5C,D).
Similarly to the Tsc2/ MEFs, the ELT3-V3 cells were almost
5-foldmore sensitive to 48 h combined treatment of nelfinavir
and chloroquine when compared to ELT3-T3 cells, as deter-
mined by DNA fragmentation (Figure 6E).
3.5. Combined nelfinavir and chloroquine effectively kills
cancer cells with over-active mTORC1
To validate our previous findings in a cancer cell line with
over-active mTORC1, NCI-H460 human lung carcinoma cells
were treated with nelfinavir and chloroquine. As a control,
rapamycin was used to inhibit mTORC1 signalling in these
cells. Similar to the MEF and ELT3 cell lines, 3 h combined nel-
finavir and chloroquine treatment reduced both phosphory-
lated rpS6 and S6K1 signalling and increased levels of LC3-II
(Figure 7A). As expected, rapamycin completely inhibited
both rpS6 and S6K1 phosphorylation. 48 h combination treat-
ment with nelfinavir and chloroquine effectively killed NCI-
H460 cells by an average of 49%which appeared to be partially
rescued by the addition of rapamycin to an average of 26%
although this trend was not significant (P ¼ 0.127, Figure 7B,
C). This suggests mTORC1 activity contributes to induction
of cell death following treatment with nelfinavir and
chloroquine.4. Discussion
In this studywe show that combination of nelfinavir and chlo-
roquine is selectively cytotoxic to Tsc2/ cells. Importantly,
we were able to directly compare the potency of this drug
combination in Tsc2/ cell lines with matched controls
expressing wild-type Tsc2. Tsc2/ cells exhibit constitutive
mTORC1 activation, high levels of basal ER stress and
impaired autophagy. We show a combination of nelfinavir
and chloroquine potentiated ER stress and affected autophagy
in Tsc2/ cells.
Unfolded proteins in the ER are not exclusively removed
via the autophagy pathway; protein aggregates are also
removed via the proteasome (Rubinsztein, 2006). Nelfinavir
has previously been shown to inhibit the proteasome (Bono
et al., 2012; Gupta et al., 2007), suggesting inhibition of the pro-
teasome allows accumulation of unfolded protein aggregates
in the ER, leading to enhanced ER stress and consequent auto-
phagy induction. Despite observing changes to the autophagy
flux upon nelfinavir and chloroquine or nelfinavir and
bafilomycin-A1 treatment, induction of cell death was exclu-
sive to the use of nelfinavir with chloroquine or its analogue,
mefloquine. In contrast to chloroquine, mefloquine did not
inhibit autophagy in the MEF cell lines (Figure 5A). Supporting
our findings, Shin et al. (2012) showed mefloquine to induce
autophagy, and combined autophagy repression with 3-MA
aggravated mefloquine-mediated cytotoxicity. Our data indi-
cates an autophagy-independent role for chloroquine is the
underlying mechanism of enhanced sensitivity to nelfinavir-
Figure 4 e Combined treatment of nelfinavir and chloroquine selectively kills Tsc2L/LMEFs. Tsc2L/L and Tsc2D/DMEFs were treated with
either DMSO vehicle alone, 20 mM nelfinavir (NFV), 20 mM chloroquine (CQ), or both NFV and CQ over 24 h and subjected to cell death assays.
A) For quantification of cell death, Tsc2D/D and Tsc2L/LMEFs were subjected to flow cytometry analysis following DRAQ7 staining. DRAQ7
exclusion (below line) represents the viable cell population, whilst positive DRAQ7 staining (above line) indicates cell death. The number of
DRAQ7-stained cells are graphed in B. C) Relative DNA fragmentation as determined by cell death ELISA. n [ 3, *p [<0.05.
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lysosomal/endosomal compartments was necessary for cyto-
toxicity, as we observed bafilomycin-A1 inhibition of v-
ATPase (Klionsky et al., 2008) prevented nelfinavir and
chloroquine-induced cell death. Our results are in accordance
with previous data showing nutrient deprivation combined
with chloroquine treatment effectively killed glioma, mela-
noma and fibrosarcoma cells which was not replicated with
bafilomycin-A1, and that addition of bafilomycin-A1 was
able to rescue the effects of chloroquine (Harhaji-Trajkovic
et al., 2012).
Cells lacking Tsc2 have a truncated ER stress response
(Kang et al., 2011), implying that TSC2 is required for a normal
response to ER stress. There are several signalling mecha-
nisms which converge upon mTORC1 during a normal ER
stress response: GADD34 recruits protein phosphatase 1
(PP1) which activates TSC2 through dephosphorylation andsubsequent inhibition of Rheb/mTORC1 (Uddin et al., 2011;
Watanabe et al., 2007; Kojima et al., 2003). As we observed
increased AMPK activation (Figure 2D), nelfinavir likely in-
hibits mTORC1 through AMPK-mediated TSC2 activation.
This method of mTORC1 inhibition through AMPK has been
previously established in Tsc2/ cells (Gwinn et al., 2008).
Interestingly, recent research by Br€uning et al. (2013) linked
AMPK activation to ER stress through the sestrin 2 (SESN2)
protein. Furthermore, their research indicated that
nelfinavir-mediated ER stress results in accumulation of Acti-
vating Transcription Factor 4 (ATF4), a known regulator of
CHOP and SESN2 (Br€uning et al., 2013). Nelfinavir also inhibits
Akt (Gupta et al., 2005; Plastaras et al., 2008), which could acti-
vate TSC2 to further repress mTORC1 signalling (Tee et al.,
2003). These various ER stress and nelfinavir TSC2-
dependent signalling mechanisms may explain why rpS6
and S6K1 phosphorylation levels were markedly reduced in
Figure 5 e Combination treatments of nelfinavir and bafilomycin-A1 or nelfinavir and 3-methyladenine fail to kill Tsc2L/LMEFs. Tsc2L/L and
Tsc2D/D MEFs were treated with either DMSO vehicle alone, 2.5 mM baflilomycin-A1 (BAF), 10 mM 3-methyladenine (3-MA), 10 mM
mefloquine (MQ) or combined nelfinavir (NFV) BAF/3-MA/MQ. A) Following 3 h drug treatment, protein lysates were subjected to western blot
analysis to determine levels of LC3-II, SQSTM1 and b-actin. B) For quantification of cell death following 48 h of treatment, Tsc2L/L and
Tsc2D/D MEFs were subjected to flow cytometry analysis following DRAQ7 staining. DRAQ7 exclusion (below line) represents the viable cell
population, whilst positive DRAQ7 staining (above line) indicates cell death. The number of DRAQ7-stained cells are graphed in C. n [ 3,
*p [<0.05.
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following nelfinavir treatment (Figures 2A and 3A). Therefore,
nelfinavir may inhibit mTORC1 signal transduction through
multiple mechanisms that require TSC2, i.e., via GADD34/
PP1/TSC2, Akt/TSC2, and/or SESN2/AMPK/TSC2, all of whichwould be compromised in Tsc2/ cells. We are currently
investigating the drug actions of nelfinavir and chloroquine
to induce cell death, and propose a mechanism in Figure 8.
TSC2 appears vital for the survival of nelfinavir and
chloroquine-treated cells. The enhanced sensitivity of Tsc2/
Figure 6 e Combined treatment of nelfinavir and chloroquine selectively kills Tsc2L/L ELT3 cells. Tsc2L/L and Tsc2D/D ELT3 cells were
treated with either DMSO vehicle alone, 20 mM nelfinavir (NFV), 20 mM chloroquine (CQ), or both NFV and CQ and subjected to western blot
and death assays. A) Following 3 h drug treatment, protein lysates were subjected to western blot analysis to determine levels of total and
phosphorylated ‘(P)-rpS6’, total and phosphorylated ‘(P)-S6K1’, LC3-II, SQSTM1, TSC2 and b-actin. B) Quantification of cell viability. C) For
quantification of cell death following 48 h of treatment, Tsc2D/D and Tsc2L/L ELT3 cells were subjected to flow cytometry analysis following
DRAQ7 staining. DRAQ7 exclusion (below line) represents the viable cell population, whilst positive DRAQ7 staining (above line) indicates cell
death. The number of DRAQ7-stained cells are graphed in D. E) Relative DNA fragmentation as determined by cell death ELISA. n [ 3,
*p [<0.05.
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Figure 7 e Combined treatment of nelfinavir and chloroquine kills NCI-H460 lung cancer cells. NCI-H460 cells were treated with either DMSO
vehicle alone, 20 mM nelfinavir (NFV), 20 mM chloroquine (CQ), or both NFV and CQ and subjected to western blot and death assays. 100 nm
rapamycin was used to inhibit mTORC1 signalling. A) Following 3 h drug treatment, protein lysates were subjected to western blot analysis to
determine levels of total and phosphorylated rpS6, total and phosphorylated S6K1, LC3-II, SQSTM1 and b-actin. B) For quantification of cell
death following 48 h of treatment, NCI-H460 cells were subjected to flow cytometry analysis following DRAQ7 staining. DRAQ7 exclusion
(below line) represents the viable cell population, whilst positive DRAQ7 staining (above line) indicates cell death. The number of DRAQ7-
stained cells are graphed in C. n [ 3.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 6 7 5e6 8 8 685 cell lines to cell death could be due in part to the inability of
nelfinavir to ablate mTORC1 signalling in these cells. One
important feature of the ER stress response pathway is to
block mTORC1 signalling for two main purposes: firstly,mTORC1 inhibition reduces the rate of protein synthesis, less-
ening the burden on the ER, and secondly, mTORC1 inhibition
is required for a robust autophagy response, allowing efficient
removal of unfolded protein aggregates in the ER. Therefore,
Figure 8 e Chloroquine augments nelfinavir-induced ER stress and
cell death independently of autophagy. In normal cells, nelfinavir-
induced ER stress inhibits mTORC1 de novo protein synthesis
through two survival pathways, GADD34 and AMPK, which both
directly activate the TSC protein complex. In TSC-deficient cells or
when mTORC1 is oncogenically activated, ER stress is less efficient
at repressing mTORC1 signalling, further enhancing ER stress
through continual protein production and autophagy inhibition.
Prolonged, elevated ER stress produces a lethal outcome in cells
unable to alleviate mTORC1 activation. Entrapment of chloroquine
to lysosomes is required for enhancement of nelfinavir-induced cell
death.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 6 7 5e6 8 8686activation of TSC2 and inhibition of mTORC1 appears to be
critically important for cell survival during acute or prolonged
ER stress. Frequent constitutive activation of mTORC1 signal-
ling in cancer suggests that our observations may have wider
relevance. In line with our work, nelfinavir effectively induced
cell death when combined with chloroquine or mefloquine in
breast cancer models (Thomas et al., 2012), medullary thyroid
cancer cell lines (Kushchayeva et al., 2014), and a model of
chronic lymphocytic leukaemia (Mahoney et al., 2013). Chloro-
quine in combination with rapamycin was also effective in
Tsc2/ MEFs (Parkhitko et al., 2011).
In conclusion, our data shows that mTORC1-hyperactive
cells are sensitive to nelfinavir-induced cell death, which is
further enhanced by chloroquine through an autophagy-
independent mechanism involving its protonation and
entrapment within lysosomes which is prevented by addition
of bafilomycin-A1. In addition to therapeutic potential in the
context of TSC and LAM, dual treatment with nelfinavir andchloroquine promises to be minimally toxic and efficacious
in a range of tumour types featuring hyper-active mTORC1.Conflict of interest
The authors have no conflicts of interest to declare.
Acknowledgements
This research was supported by the Association for Interna-
tional Cancer Research Career Development Fellowship [No.
06-914/915] and the Tuberous Sclerosis Association awarded
to A. Tee, a BBSRC Research Equipment Initiative [BB/
E012574/1] awarded to R.J. Errington. Additional support was
provided from the National Institute for Social Care and
Health Research (NISCHR), theWales Gene Park, the Tuberous
Sclerosis Association and the Cardiff University School of
Medicine.R E F E R E N C E S
Alonso-Basanta, M., Fang, P., Maity, A., Hahn, S.M., Lustig, R.A.,
Dorsey, J.F., 2014. A phase I study of nelfinavir concurrent with
temozolomide and radiotherapy in patients with glioblastoma
multiforme. J. Neurooncol. 116, 365e372.
Appenzeller-Herzog, C., Hall, M.N., 2012. Bidirectional crosstalk
between endoplasmic reticulum stress and mTOR signaling.
Trends Cell Biol. 22, 274e282.
Bono, C., Karlin, L., Harel, S., Mouly, E., Labaume, S., Galicier, L.,
Apcher, S., Sauvageon, H., Fermand, J.P., Bories, J.C., Arnulf, B.,
2012. The human immunodeficiency virus-1 protease
inhibitor nelfinavir impairs proteasome activity and inhibits
the proliferation of multiple myeloma cells in vitro and
in vivo. Haematologica 97, 1101e1109.
Br€uning, A., 2011. Analysis of nelfinavir-induced endoplasmic
reticulum stress. Method Enzymol. 491, 127e142.
Br€uning, A., Rahmeh, M., Friese, K., 2013. Nelfinavir and
bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2
regulation. Mol. Oncol. 6, 1012e1018.
Buijsen, J., Lammering, G., Jansen, R.L., Beets, G.L., Wals, J.,
Sosef, M., Den Boer, M.O., Leijtens, J., Riedl, R.G., Theys, J.,
Lambin, P., 2013. Phase I trial of the combination of the Akt
inhibitor nelfinavir and chemoradiation for locally advanced
rectal cancer. Radiother. Oncol. 107, 184e188.
Di Nardo, A., Kramvis, I., Cho, N., Sadowski, A., Meikle, L.,
Kwiatkowski, D.J., Sahin, M., 2009. Tuberous sclerosis complex
activity is required to control neuronal stress responses in an
mTOR-dependent manner. J. Neurosci. 29, 5926e5937.
Dibble, C.C., Elis, W., Menon, S., Qin, W., Klekota, J., Asara, J.M.,
Finan, P.M., Kwiatkowski, D.J., Murphy, L.O., Manning, B.D.,
2012. TBC1D7 is a third subunit of the TSC1eTSC2 complex
upstream of mTORC1. Mol. Cell 47, 535e546.
Dunlop, E.A., Hunt, D.K., Acosta-Jaquez, H.A., Fingar, D.C.,
Tee, A.R., 2011. ULK1 inhibits mTORC1 signaling, promotes
multisite Raptor phosphorylation and hinders substrate
binding. Autophagy 7, 737e747.
Eker, P., Eker, R., Johannessen, J.V., 1983. Establishment and
characterization of a new cell line from a hereditary renal rat
tumor. In Vitro 19, 495e503.
Franz, D.N., Weiss, B.D., 2012 Jun. Molecular therapies for
tuberous sclerosis and neurofibromatosis. Curr. Neurol.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 6 7 5e6 8 8 687Neurosci. Rep. 12 (3), 294e301. http://dx.doi.org/10.1007/
s11910-012-0269-4 [Review].
Ganley, I.G., Wong, P.M., Gammoh, N., Jiang, X., 2011. Distinct
autophagosomalelysosomal fusion mechanism revealed by
thapsigargin-induced autophagy arrest. Mol. Cell 42,
731e743.
Gills, J.J., Lopiccolo, J., Tsurutani, J., Shoemaker, R.H., Best, C.J.,
Abu-Asab, M.S., Borojerdi, J., Warfel, N.A., Gardner, E.R.,
Danish, M., Hollander, M.C., Kawabata, S., Tsokos, M.,
Figg, W.D., Steeg, P.S., Dennis, P.A., 2007. Nelfinavir, a lead HIV
protease inhibitor, is a broad-spectrum, anticancer agent that
induces endoplasmic reticulum stress, autophagy, and
apoptosis in vitro and in vivo. Clin. Cancer Res. 13, 5183e5194.
Goldberg, S.B., Supko, J.G., Neal, J.W., Muzikansky, A.,
Digumarthy, S., Fidias, P., Temel, J.S., Heist, R.S., Shaw, A.T.,
McCarthy, P.O., Lynch, T.J., Sharma, S., Settleman, J.E.,
Sequist, L.V., 2012. A phase I study of erlotinib and
hydroxychloroquine in advanced non-small-cell lung cancer.
J. Thorac. Oncol. 7, 1602e1608.
Gupta, A.K., Cerniglia, G.J., Mick, R., McKenna, W.G., Muschel, R.J.,
2005. HIV protease inhibitors block Akt signaling and
radiosensitize tumor cells both in vitro and in vivo. Cancer
Res. 65, 8256e8265.
Gupta, A.K., Li, B., Cerniglia, G.J., Ahmed, M.S., Hahn, S.M.,
Maity, A., 2007. The HIV protease inhibitor nelfinavir
downregulates Akt phosphorylation by inhibiting proteasomal
activity and inducing the unfolded protein response.
Neoplasia 9, 271e278.
Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M.,
Mery, A., Vasquez, D.S., Turk, B.E., Shaw, R.J., 2008. AMPK
phosphorylation of raptor mediates a metabolic checkpoint.
Mol. Cell 30, 214e226.
Hanahan, D., Weinberg, R.A., 2011. Hallmarks of cancer: the next
generation. Cell 144, 646e674.
Harhaji-Trajkovic, L., Arsikin, K., Kravic-Stevovic, T.,
Petricevic, S., Tovilovic, G., Pantovic, A., Zogovic, N., Ristic, B.,
Janjetovic, K., Bumbasirevic, V., Trajkovic, V., 2012.
Chloroquine-mediated lysosomal dysfunction enhances the
anticancer effect of nutrient deprivation. Pharm. Res. 29,
2249e2263.
He, C., Klionsky, D.J., 2009. Regulation mechanisms and signaling
pathways of autophagy. Annu. Rev. Genet. 43, 67e93.
Høyer-Hansen, M., J€a€attel€a, M., 2007. Connecting endoplasmic
reticulum stress to autophagy by unfolded protein response
and calcium. Cell Death Differ. 14, 1576e1582.
Jiao, Y., Shi, C., Edil, B.H., de Wilde, R.F., Klimstra, D.S., Maitra, A.,
Schulick, R.D., Tang, L.H., Wolfgang, C.L., Choti, M.A.,
Velculescu, V.E., Diaz Jr., L.A., Vogelstein, B., Kinzler, K.W.,
Hruban, R.H., Papadopoulos, N., 2011. DAXX/ATRX, MEN1, and
mTOR pathway genes are frequently altered in pancreatic
neuroendocrine tumors. Science 331, 1199e1203.
Kang, Y.J., Lu, M.K., Guan, K.L., 2011. The TSC1 and TSC2 tumor
suppressors are required for proper ER stress response and
protect cells from ER stress-induced apoptosis. Cell Death
Differ. 18, 133e144.
Klionsky, D.J., Elazar, Z., Seglen, P.O., Rubinsztein, D.C., 2008.
Does bafilomycin A1 block the fusion of autophagosomes with
lysosomes? Autophagy 4, 849e850.
Kohrman, M.H., 2012. Emerging treatments in the management of
tuberous sclerosis complex. Pediatr. Neurol. 46, 267e275.
Kojima, E., Takeuchi, A., Haneda, M., Yagi, A., Hasegawa, T.,
Yamaki, K., Takeda, K., Akira, S., Shimokata, K., Isobe, K., 2003.
The function of GADD34 is a recovery from a shutoff of protein
synthesis induced by ER stress: elucidation by GADD34-
deficient mice. FASEB J. 17, 1573e1575.
Krymskaya, V.P., Goncharova, E.A., 2009. PI3K/mTORC1 activation
in hamartoma syndromes: therapeutic prospects. Cell Cycle 8,
403e413.Kushchayeva, Y., Jensen, K., Recupero, A., Costello, J., Patel, A.,
Klubo-Gwiezdzinska, J., Boyle, L., Burman, K., Vasko, V., 2014.
The HIV protease inhibitor nelfinavir downregulates RET
signaling and induces apoptosis in medullary thyroid Cancer
cells. J. Clin. Endocrinol. Metab. 99, E734eE745.
Li, T., Su, L., Zhong, N., Hao, X., Zhong, D., Singhal, S., Liu, X., 2013.
Salinomycin induces cell death with autophagy through
activation of endoplasmic reticulum stress in human cancer
cells. Autophagy 9, 1057e1068.
Liao, Y.M., Kim, C., Yen, Y., 2011. Mammalian target of rapamycin
and head and neck squamous cell carcinoma. Head Neck
Oncol. 3, 22.
Liu, G., Su, L., Hao, X., Zhong, N., Zhong, D., Singhal, S., Liu, X.,
2012. Salermide up-regulates death receptor 5 expression
through the ATF4eATF3eCHOP axis and leads to apoptosis in
human cancer cells. J. Cell. Mol. Med. 16, 1618e1628.
Mahoney, E., Maddocks, K., Flynn, J., Jones, J., Cole, S.L., Zhang, X.,
Byrd, J.C., Johnson, A.J., 2013. Identification of endoplasmic
reticulum stress-inducing agents by antagonizing autophagy:
a new potential strategy for identification of anti-cancer
therapeutics in B-cell malignancies. Leuk. Lymphoma 54,
2685e2692.
Maycotte, P., Aryal, S., Cummings, C.T., Thorburn, J., Morgan, M.J.,
Thornburn, A., 2012. Chloroquine sensitizes breast cancer
cells to chemotherapy independent of autophagy. Autophagy
8, 200e212.
Ozcan, U., Ozcan, L., Yilmaz, E., Duvel, K., Sahin, M.,
Manning, B.D., Hotamisligil, G.S., 2008. Loss of the tuberous
sclerosis complex tumor suppressors triggers the unfolded
protein response to regulate insulin signaling and apoptosis.
Mol. Cell 29, 541e551.
Pan, J., Mott, M., Xi, B., Hepner, E., Guan, M., Fousek, K.,
Magnusson, R., Tinsley, R., Valdes, F., Frankel, P., Synold, T.,
Chow, W.A., 2012. Phase I study of nelfinavir in liposarcoma.
Cancer Chemother. Pharmacol. 70, 791e799.
Parkhitko, A., Myachina, F., Morrison, T.A., Hindi, K.M.,
Auricchio, N., Karbowniczek, M., Wu, J.J., Finkel, T.,
Kwiatkowski, D.J., Yu, J.J., Henske, E.P., 2011. Tumorigenesis in
tuberous sclerosis complex is autophagy and p62/
sequestosome 1 (SQSTM1)-dependent. Proc. Natl. Acad. Sci. U.
S. A. 108, 12455e12460.
Plastaras, J.P., Vapiwala, N., Ahmed, M.S., Gudonis, D.,
Cerniglia, G.J., Feldman, M.D., Frank, I., Gupta, A.K., 2008.
Validation and toxicity of PI3K/Akt pathway inhibition by HIV
protease inhibitors in humans. Cancer Biol. Ther. 7, 628e635.
Platt, F.M., Hurst, C.D., Taylor, C.F., Gregory, W.M., Harnden, P.,
Knowles, M.A., 2009. Spectrum of phosphatidylinositol 3-
kinase pathway gene alterations in bladder cancer. Clin.
Cancer Res. 15, 6008e6017.
Poole, B., Ohkuma, S., 1981. Effect of weak bases on the
intralysosomal pH in mouse peritoneal macrophages. J. Cell
Biol. 90, 665e669.
Rengan, R., Mick, R., Pryma, D., Rosen, M.A., Lin, L.L., Maity, A.M.,
Evans, T.L., Stevenson, J.P., Langer, C.J., Kucharczuk, J.,
Friedberg, J., Prendergast, S., Sharkoski, T., Hahn, S.M., 2012.
A phase I trial of the HIV protease inhibitor nelfinavir with
concurrent chemoradiotherapy for unresectable stage IIIA/IIIB
non-small cell lung cancer: a report of toxicities and clinical
response. J. Thorac. Oncol. 7, 709e715.
Rubinsztein, D.C., 2006. The roles of intracellular protein-
degradation pathways in neurodegeneration. Nature 443,
780e786.
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y.,
Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G.,
Suzuki, H., Nagata, Y., Yoshida, K., Kon, A., Suzuki, Y.,
Chiba, K., Tanaka, H., Niida, A., Fujimoto, A., Tsunoda, T.,
Morikawa, T., Maeda, D., Kume, H., Sugano, S., Fukayama, M.,
Aburatani, H., Sanada, M., Miyano, S., Homma, Y., Ogawa, S.,
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 6 7 5e6 8 86882013. Integrated molecular analysis of clear-cell renal cell
carcinoma. Nat. Genet. 45, 860e867.
Seitz, C., Hugle, M., Cristofanon, S., Tchoghandjian, A., Fulda, S.,
2013. The dual PI3K/mTOR inhibitor NVP-BEZ235 and
chloroquine synergize to trigger apoptosis via
mitochondrialelysosomal cross-talk. Int. J. Cancer 132,
2682e2693.
Shin, J.H., Park, S.J., Jo, Y.K., Kim, E.S., Kang, H., Park, J.H.,
Lee, E.H., Cho, D.H., 2012. Suppression of autophagy
exacerbates Mefloquine-mediated cell death. Neurosci. Lett.
515, 162e167.
Siroky, B.J., Yin, H., Babcock, J.T., Lu, L., Hellmann, A.R.,
Dixon, B.P., Quilliam, L.A., Bissler, J.J., 2012. Human TSC-
associated renal angiomyolipoma cells are hypersensitive to
ER stress. Am. J. Physiol. Renal Physiol. 303, 831e844.
Sjodahl, G., Lauss, M., Gudjonsson, S., Liedberg, F., Hallden, C.,
Chebil, G., Mansson, W., Hoglund, M., Lindgren, D., 2011. A
systematic study of gene mutations in urothelial carcinoma;
inactivating mutations in TSC2 and PIK3R1. PLoS ONE 6,
e18583.
Solomon, V.R., Lee, H., 2009. Chloroquine and its analogs: a new
promise of an old drug for effective and safe cancer therapies.
Eur. J. Pharmacol. 625, 220e233.
Sotelo, J., Briceno, E., Lopez-Gonzalez, M.A., 2006. Adding
chloroquine to conventional treatment for glioblastoma
multiforme: a randomized, double-blind, placebo-controlled
trial. Ann. Intern. Med. 144, 337e343.
Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C., Blenis, J., 2003.
Tuberous sclerosis complex gene products, tuberin andhamartin, control mTOR signaling by acting as a GTPase-
activating protein complex toward Rheb. Curr. Biol. 13,
1259e1268.
Thomas, S., Sharma, N., Golden, E.B., Cho, H., Agarwal, P.,
Gaffney, K.J., Petasis, N.A., Chen, T.C., Hofman, F.M.,
Louie, S.G., Schonthal, A.H., 2012. Preferential killing of triple-
negative breast cancer cells in vitro and in vivo when
pharmacological aggravators of endoplasmic reticulum stress
are combined with autophagy inhibitors. Cancer Lett. 325,
63e71.
Uddin, M.N., Ito, S., Nishio, N., Suganya, T., Isobe, K., 2011. Gadd34
induces autophagy through the suppression of the mTOR
pathway during starvation. Biochem. Biophys. Res. Commun.
407, 692e698.
Watanabe, R., Tambe, Y., Inoue, H., Isono, T., Haneda, M.,
Isobe, K., Kobayashi, T., Hino, O., Okabe, H., Chano, T., 2007.
GADD34 inhibits mammalian target of rapamycin signaling
via tuberous sclerosis complex and controls cell survival
under bioenergetic stress. Int. J. Mol. Med. 19, 475e483.
Wu, Y.T., Tan, H.L., Shui, G., Bauvy, C., Huang, Q., Wenk, M.R.,
Ong, C.N., Codogno, P., Shen, H.M., 2010. Dual role of 3-
methyladenine in modulation of autophagy via different
temporal patterns of inhibition on class I and III
phosphoinositide 3-kinase. J. Biol. Chem. 285, 10850e10861.
Zang, C., Liu, H., Bertz, J., Possinger, K., Koeffler, H.P., Elstner, E.,
Eucker, J., 2009. Induction of endoplasmic reticulum stress
response by TZD18, a novel dual ligand for peroxisome
proliferator-activated receptor alpha/gamma, in human
breast cancer cells. Mol. Cancer Ther. 8, 2296e2307.
